Alliance for Pandemic Preparedness

March 17, 2021

Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands

Category:

Topic:

Keywords (Tags): ,

  • Evaluation of the Roche SD Biosensor rapid antigen test for SARS-CoV-2 among asymptomatic outpatients demonstrated that test sensitivity was 84.9% and specificity was 99.5%. Around 98% of samples with a cycle threshold (Ct) below 30 (indicating higher viral load) were detected. Test sensitivity was higher (95.8%) among people who sought care within 7 days of experiencing symptoms. 

Iglói et al. (Mar 16, 2021). Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. Emerging Infectious Diseases. https://wwwnc.cdc.gov/eid/article/27/5/20-4688_article